— Know what they know.
Not Investment Advice

SLDB NASDAQ

Solid Biosciences Inc.
1W: -14.8% 1M: -22.6% 3M: +13.8% YTD: +19.3% 1Y: +120.3% 3Y: +3.8% 5Y: -87.6%
$6.62
+0.12 (+1.85%)
 
Weekly Expected Move ±8.8%
$6 $6 $7 $8 $8
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 33 · $515.8M mcap · 60M float · 2.16% daily turnover · Short 52% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
30.1 / 100
NoneWeakNarrowWide
Primary source: Network Effects  ·  ROIC: -1165.1%  ·  5Y Avg: -221.0%
Cost Advantage
33
Intangibles
25
Switching Cost
30
Network Effect
43
Scale
22
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. SLDB has No discernible competitive edge (30.1/100). The business operates without significant structural advantages. The primary source of advantage is Network Effects. Negative ROIC of -1165.1% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$16
Low
$17
Avg Target
$18
High
Based on 2 analysts since May 12, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 16Hold: 5Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$17.00
Analysts2
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-13 Wedbush Initiated $16 +106.8% $7.74
2026-05-13 Piper Sandler Biren Amin $20 $18 -2 +133.2% $7.72
2025-12-04 Needham Gil Blum Initiated $16 +208.3% $5.19
2025-11-04 Barclays $18 $9 -9 +73.1% $5.20
2025-07-21 Cantor Fitzgerald Charles Duncan Initiated $16 +136.7% $6.76
2024-06-24 Leerink Partners Joseph Schwartz Initiated $12 +81.3% $6.62
2024-05-31 Piper Sandler Biren Amin Initiated $20 +161.8% $7.64
2024-05-16 Barclays Gena Wang Initiated $18 +85.8% $9.69
2024-03-13 Raymond James Christopher Raymond Initiated $20 +63.5% $12.23

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C+
May 22, 2026
DCF
3
ROE
1
ROA
1
D/E
3
P/E
1
P/B
3
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. SLDB receives an overall rating of C+. Areas of concern: ROE (1/5), ROA (1/5), P/E (1/5).
Rating Change History
DateFromTo
2026-05-14 C- C+
2026-05-12 C C-
2026-05-04 C- C
2026-04-27 C C-
2026-03-23 C- C
2026-03-19 C C-
2026-03-12 C+ C

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

Grade A+
Profitability
Balance Sheet
0
Earnings Quality
51
Growth
Value
36
Momentum
Safety
30
Cash Flow

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
1.43
Distress Zone
Piotroski F-Score
3/9
Beneish M-Score
Ohlson O-Score
-0.54
Bankruptcy prob: 36.8%
Moderate
Credit Rating
BB
Score: 42.3/100
Trend: Improving
Earnings Quality
OCF/NI: 0.90x
Accruals: -9.5%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. SLDB scores 1.43, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. SLDB scores 3/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. SLDB's implied 36.8% bankruptcy probability is elevated and warrants attention to the balance sheet. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. SLDB receives an estimated rating of BB (score: 42.3/100), with a improving trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-3.79x
PEG
-0.10x
P/S
0.00x
P/B
1.94x
P/FCF
-4.57x
P/OCF
EV/EBITDA
-3.28x
EV/Revenue
EV/EBIT
-3.25x
EV/FCF
-3.61x
Earnings Yield
-24.26%
FCF Yield
-21.86%
Shareholder Yield
0.00%
Graham Number
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. SLDB currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.000
NI / EBT
×
Interest Burden
0.999
EBT / EBIT
×
EBIT Margin
EBIT / Rev
×
Asset Turnover
0.000
Rev / Assets
×
Equity Multiplier
1.328
Assets / Equity
=
ROE
-120.9%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. SLDB's ROE of -120.9% is driven by A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
Price/Value
Margin of Safety
Premium
Assessment
Overvalued

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$6.62
Median 1Y
$2.37
5th Pctile
$0.46
95th Pctile
$12.09
Ann. Volatility
109.4%
Analyst Target
$17.00
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Alexander Cumbo,
President and Chief Executive Officer
$650,988 $2,318,275 $5,223,442
David Tyronne Howton,
Chief Operating Officer and Secretary
$513,422 $1,000,488 $2,588,827
Gabriel Brooks, M.D.,
Chief Medical Officer
$502,164 $798,634 $2,328,156

CEO Pay Ratio

5374:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $5,223,442
Avg Employee Cost (SGA/emp): $972
Employees: 40,000

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
40,000
+39900.0% YoY
Revenue / Employee
Profit / Employee
$-4,358
NI: $-174,325,000
SGA / Employee
$972
Avg labor cost proxy
R&D / Employee
$3,508
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE -73.7% -70.7% -42.4% -47.4% -51.1% -52.6% -41.0% -43.2% -43.0% -43.3% -56.8% -53.4% -53.6% -60.6% -94.6% -1.1% -1.2% -1.3% -1.1% -1.2% -1.21%
ROA -57.0% -54.6% -35.8% -40.0% -43.1% -44.3% -34.9% -36.8% -36.6% -36.9% -45.2% -42.5% -42.7% -48.2% -70.5% -79.0% -87.2% -94.5% -82.8% -91.1% -91.06%
ROIC 3.5% 3.4% -22.9% -25.6% -27.7% -28.7% -3.2% -3.4% -3.4% -3.5% -2.8% -2.7% -2.7% -3.0% -8.2% -9.0% -9.9% -10.7% -10.6% -11.7% -11.65%
ROCE -53.3% -51.1% -34.6% -38.7% -41.2% -42.6% -41.8% -43.7% -44.0% -43.8% -64.9% -61.1% -61.4% -69.2% -78.5% -88.0% -97.1% -1.1% -87.3% -96.4% -96.40%
Gross Margin 1.0% 1.0% 1.0% 1.0% 1.0%
Operating Margin -5.2% -5.1% -5.9% -13.2% -4.1%
Net Margin -5.2% -5.1% -5.9% -13.2% -4.1%
EBITDA Margin -5.0% -4.9% -5.7% -12.8% -3.8%
FCF Margin -7.7% -5.4% -5.8% -7.0% -5.7% -7.8% -12.5% -16.6%
OCF Margin -7.6% -5.3% -5.7% -6.8% -5.6% -7.5% -12.1% -16.0%
ROE 3Y Avg snapshot only -93.22%
ROE 5Y Avg snapshot only -72.25%
ROA 3Y Avg snapshot only -70.41%
ROIC Economic snapshot only -77.15%
Cash ROA snapshot only -73.82%
Cash ROIC snapshot only -12.89%
CROIC snapshot only -12.98%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio -5.26 -3.58 -2.72 -1.68 -0.80 -0.59 -0.50 -1.02 -1.14 -0.56 -1.86 -5.63 -2.56 -2.82 -1.72 -1.76 -2.98 -3.49 -3.06 -4.12 -3.791
P/S Ratio 59.32 25.64 14.43 11.07 4.70 4.69 5.33 15.03 0.000
P/B Ratio 3.11 2.03 0.94 0.65 0.33 0.25 0.20 0.44 0.49 0.24 1.41 4.02 1.84 2.28 1.56 1.79 3.34 4.24 2.97 4.39 1.943
P/FCF -7.72 -4.77 -2.49 -1.59 -0.82 -0.61 -0.43 -0.91 -0.91 -0.46 -1.86 -5.49 -2.69 -3.15 -2.13 -2.29 -3.72 -4.37 -3.39 -4.57 -4.574
P/OCF
EV/EBITDA -3.48 -1.65 0.13 0.91 1.64 1.77 1.47 0.91 0.81 1.33 -0.85 -4.56 -1.50 -1.88 -0.73 -0.88 -2.19 -2.77 -2.13 -3.28 -3.279
EV/Revenue 37.73 11.34 -0.67 -5.78 -9.21 -13.59 -17.55 -14.98
EV/EBIT -3.35 -1.58 0.13 0.87 1.59 1.72 1.43 0.89 0.79 1.29 -0.83 -4.47 -1.46 -1.84 -0.72 -0.87 -2.17 -2.74 -2.11 -3.25 -3.251
EV/FCF -4.91 -2.11 0.12 0.83 1.61 1.75 1.41 0.91 0.73 1.22 -0.84 -4.44 -1.56 -2.09 -0.89 -1.13 -2.71 -3.44 -2.33 -3.61 -3.610
Earnings Yield -19.0% -27.9% -36.7% -59.7% -1.3% -1.7% -2.0% -97.8% -87.6% -1.8% -53.9% -17.8% -39.1% -35.5% -58.2% -56.9% -33.6% -28.7% -32.6% -24.3% -24.26%
FCF Yield -13.0% -21.0% -40.2% -62.9% -1.2% -1.7% -2.3% -1.1% -1.1% -2.2% -53.7% -18.2% -37.2% -31.8% -47.0% -43.7% -26.9% -22.9% -29.5% -21.9% -21.86%
Price/Tangible Book snapshot only 4.392
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 6.49 6.49 9.43 9.43 9.43 9.43 9.76 9.76 9.76 9.76 8.94 8.94 8.94 8.94 5.20 5.20 5.20 5.20 6.14 6.14 6.138
Quick Ratio 6.49 6.49 9.43 9.43 9.43 9.43 9.76 9.76 9.76 9.76 8.94 8.94 8.94 8.94 5.20 5.20 5.20 5.20 6.14 6.14 6.138
Debt/Equity 0.04 0.04 0.01 0.01 0.01 0.01 0.13 0.13 0.13 0.13 0.21 0.21 0.21 0.21 0.18 0.18 0.18 0.18 0.12 0.12 0.118
Net Debt/Equity -1.13 -1.13 -0.99 -0.99 -0.99 -0.99 -0.87 -0.87 -0.87 -0.87 -0.77 -0.77 -0.77 -0.77 -0.91 -0.91 -0.91 -0.91 -0.93 -0.93 -0.926
Debt/Assets 0.03 0.03 0.01 0.01 0.01 0.01 0.11 0.11 0.11 0.11 0.16 0.16 0.16 0.16 0.13 0.13 0.13 0.13 0.09 0.09 0.091
Debt/EBITDA -0.07 -0.07 -0.03 -0.03 -0.02 -0.02 -0.29 -0.28 -0.28 -0.28 -0.28 -0.29 -0.29 -0.26 -0.20 -0.18 -0.16 -0.15 -0.12 -0.11 -0.111
Net Debt/EBITDA 1.99 2.08 2.97 2.64 2.48 2.38 1.91 1.83 1.82 1.83 1.02 1.08 1.08 0.96 1.02 0.91 0.82 0.75 0.97 0.88 0.876
Interest Coverage -1240.38 -1743.00 -2676.07 -6210.77 -858.27 -450.46 -308.43 -288.78 -294.44 -319.48 -392.83 -365.76 -445.25 -539.65 -822.33 -1357.91 -3198.45 -3198.450
Equity Multiplier 1.30 1.30 1.12 1.12 1.12 1.12 1.23 1.23 1.23 1.23 1.30 1.30 1.30 1.30 1.37 1.37 1.37 1.37 1.29 1.29 1.292
Cash Ratio snapshot only 5.612
Debt Service Coverage snapshot only -3171.383
Cash to Debt snapshot only 8.877
FCF to Debt snapshot only -8.169
Defensive Interval snapshot only 350.4 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.05 0.08 0.07 0.06 0.07 0.06 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Inventory Turnover
Receivables Turnover 247.64 222.00 268.82 204.51 147.16 112.16 0.00 0.00
Payables Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.12 0.12 0.12 0.10 0.13 0.25 0.25 0.21 0.21 0.209
DSO 0 0 1 2 1 2 2 3
DIO 0 0 0 0 0 0 0 0 0 0.0 days
DPO 2941 2941 2941 3499 2811 1443 1443 1717 1743 1743.4 days
Cash Conversion Cycle
Fixed Asset Turnover snapshot only 0.000
Cash Velocity snapshot only 0.000
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 2.7% 1.1% 7.5% -40.6% -49.5% -1.0% -1.0% -1.0% -1.0%
Net Income 26.8% 24.1% 18.2% -2.7% -11.3% -19.3% -19.1% -12.5% -3.7% -1.6% -11.7% 0.5% -0.5% -12.8% -29.9% -54.8% -69.9% -63.2% -39.8% -37.3% -37.30%
EPS 68.6% 67.4% 48.6% 18.6% -10.7% -18.6% -11.2% 56.8% 60.3% 61.9% 69.1% 49.0% 51.7% 45.4% 29.7% 11.0% 26.1% 28.4% 20.9% 17.0% 17.05%
FCF 37.3% 30.2% -37.5% -73.7% -58.9% -55.0% -27.8% -20.1% -33.7% -26.3% 5.2% 9.4% 23.7% 16.7% -5.2% -16.0% -42.9% -45.2% -56.4% -61.1% -61.10%
EBITDA 26.3% 23.1% 16.1% -4.0% -10.4% -20.1% -39.8% -29.9% -22.6% -17.3% 1.9% 10.9% 11.6% -0.6% -28.3% -52.0% -69.1% -62.2% -41.2% -39.1% -39.07%
Op. Income 27.6% 24.6% 18.3% -2.9% -11.9% -20.8% -47.3% -40.1% -31.0% -28.7% 2.1% 12.4% 12.7% 3.8% -24.4% -44.2% -56.8% -51.4% -38.1% -37.5% -37.46%
OCF Growth snapshot only -60.93%
Asset Growth snapshot only 23.26%
Equity Growth snapshot only 31.16%
Debt Growth snapshot only -12.47%
Shares Change snapshot only 65.53%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y
Revenue 5Y
EPS 3Y
EPS 5Y
Net Income 3Y
Net Income 5Y
EBITDA 3Y
EBITDA 5Y
Gross Profit 3Y
Gross Profit 5Y
Op. Income 3Y
Op. Income 5Y
FCF 3Y
FCF 5Y
OCF 3Y
OCF 5Y
Assets 3Y 31.0% 31.0% 18.5% 18.5% 18.5% 18.5% 36.0% 36.0% 36.0% 36.0% -1.2% -1.2% -1.2% -1.2% -6.7% -6.7% -6.7% -6.7% -3.7% -3.7% -3.68%
Assets 5Y 27.8% 27.8% 27.8% 3.4% 3.4% 3.4% 3.4% 12.8% 12.8% 12.8% 12.8% 6.3% 6.3% 6.32%
Equity 3Y 18.5% 18.5% 18.5% 18.5% 38.3% 38.3% 38.3% 38.3% -1.4% -1.4% -1.4% -1.4% -13.0% -13.0% -13.0% -13.0% -5.3% -5.3% -5.26%
Book Value 3Y -19.9% -19.9% -19.9% -13.8% 1.8% -24.3% -24.4% -24.8% -46.2% -46.9% -44.1% -44.3% -54.8% -57.9% -62.5% -62.5% -58.4% -46.7% -46.69%
Dividend 3Y
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 0.60 0.60 0.60 0.80 0.88 0.83 0.54 0.54 0.14 0.12 0.07 0.03 0.00 0.02 0.04 0.04 0.05 0.05 0.05 0.44 0.442
Earnings Stability 0.32 0.09 0.05 0.27 0.24 0.09 0.04 0.26 0.22 0.10 0.00 0.06 0.16 0.02 0.04 0.15 0.29 0.49 0.73 0.78 0.776
Margin Stability 1.00 1.00
Rev. Growth Consistency 0.50 0.50 0.50 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Earn. Growth Consistency 0.50 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.89 0.90 0.93 0.99 0.95 0.92 0.92 0.95 0.99 0.99 0.95 1.00 1.00 0.95 0.88 0.50 0.50 0.50 0.84 0.85 0.851
Earnings Smoothness
ROE Trend 0.46 0.48 0.72 0.62 0.55 0.47 0.10 0.06 0.08 0.07 -0.38 -0.31 -0.29 -0.38 -0.33 -0.45 -0.55 -0.60 -0.13 -0.20 -0.200
Gross Margin Trend 0.00
FCF Margin Trend -5.73
Sustainable Growth Rate
Internal Growth Rate
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 0.67 0.74 1.08 1.04 0.95 0.94 1.14 1.09 1.22 1.19 0.98 1.01 0.94 0.89 0.80 0.76 0.80 0.79 0.90 0.90 0.895
FCF/OCF 1.01 1.01 1.02 1.02 1.03 1.03 1.03 1.03 1.02 1.02 1.02 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.007
FCF/Net Income snapshot only 0.901
CapEx/Revenue 7.6% 6.5% 9.4% 11.7% 15.0% 25.1% 37.2% 54.1%
CapEx/Depreciation snapshot only 0.734
Accruals Ratio -0.19 -0.14 0.03 0.01 -0.02 -0.03 0.05 0.03 0.08 0.07 -0.01 0.01 -0.02 -0.05 -0.14 -0.19 -0.18 -0.20 -0.09 -0.10 -0.095
Sloan Accruals snapshot only 0.206
Cash Flow Adequacy snapshot only -144.018
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio
FCF Payout Ratio
Total Payout Ratio
Div. Increase Streak
Chowder Number
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.8% 2.4% 2.1% 1.1% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -65.0% -99.7% -68.6% -0.2% 0.0% 0.0% -1.7% -78.2% -72.9% -1.5% -1.7% -22.6% -50.7% -40.1% -57.0% -81.5% -42.1% -33.7% -36.4% -31.0% -30.97%
Total Shareholder Return -65.0% -99.7% -68.6% -0.2% 0.0% 0.0% -1.7% -78.2% -72.9% -1.5% -1.7% -22.6% -50.7% -40.1% -57.0% -81.5% -42.1% -33.7% -36.4% -31.0% -30.97%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Interest Burden (EBT/EBIT) 1.00 1.00 1.00 1.00 1.01 1.00 0.87 0.87 0.86 0.87 0.98 0.98 0.98 0.98 1.00 1.00 1.00 1.00 1.00 1.00 0.999
EBIT Margin -11.28 -7.16 -5.30 -6.61 -5.81 -7.91 -12.27 -16.83
Asset Turnover 0.05 0.08 0.07 0.06 0.07 0.06 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Equity Multiplier 1.29 1.29 1.19 1.19 1.19 1.19 1.17 1.17 1.17 1.17 1.26 1.26 1.26 1.26 1.34 1.34 1.34 1.34 1.33 1.33 1.328
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $-10.45 $-10.01 $-9.64 $-10.74 $-11.56 $-11.87 $-10.72 $-4.64 $-4.59 $-4.53 $-3.31 $-2.37 $-2.22 $-2.47 $-2.33 $-2.11 $-1.64 $-1.77 $-1.84 $-1.75 $-1.75
Book Value/Share $17.64 $17.65 $27.81 $27.74 $27.67 $27.64 $26.38 $10.82 $10.76 $10.55 $4.36 $3.31 $3.09 $3.05 $2.56 $2.07 $1.46 $1.45 $1.90 $1.64 $3.41
Tangible Book/Share $17.64 $17.65 $27.81 $27.74 $27.67 $27.64 $26.38 $10.82 $10.76 $10.55 $4.36 $3.31 $3.09 $3.05 $2.56 $2.07 $1.46 $1.45 $1.90 $1.64 $1.64
Revenue/Share $0.93 $1.40 $1.82 $1.63 $1.97 $1.49 $1.01 $0.32 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
FCF/Share $-7.11 $-7.52 $-10.56 $-11.33 $-11.24 $-11.57 $-12.59 $-5.22 $-5.75 $-5.49 $-3.30 $-2.43 $-2.11 $-2.21 $-1.88 $-1.62 $-1.31 $-1.41 $-1.66 $-1.57 $-1.57
OCF/Share $-7.04 $-7.43 $-10.39 $-11.13 $-10.95 $-11.20 $-12.21 $-5.05 $-5.61 $-5.38 $-3.25 $-2.39 $-2.09 $-2.20 $-1.87 $-1.61 $-1.30 $-1.40 $-1.65 $-1.56 $-1.56
Cash/Share $20.67 $20.68 $27.75 $27.68 $27.62 $27.58 $26.64 $10.92 $10.87 $10.65 $4.26 $3.24 $3.02 $2.98 $2.78 $2.24 $1.58 $1.58 $1.98 $1.71 $3.47
EBITDA/Share $-10.03 $-9.61 $-9.25 $-10.36 $-11.03 $-11.47 $-12.07 $-5.17 $-5.17 $-5.05 $-3.27 $-2.36 $-2.20 $-2.46 $-2.28 $-2.06 $-1.62 $-1.75 $-1.82 $-1.73 $-1.73
Debt/Share $0.69 $0.69 $0.28 $0.27 $0.27 $0.27 $3.56 $1.46 $1.45 $1.42 $0.91 $0.69 $0.64 $0.63 $0.45 $0.36 $0.26 $0.26 $0.22 $0.19 $0.19
Net Debt/Share $-19.98 $-19.99 $-27.47 $-27.40 $-27.34 $-27.31 $-23.08 $-9.46 $-9.42 $-9.23 $-3.36 $-2.55 $-2.38 $-2.35 $-2.33 $-1.88 $-1.33 $-1.32 $-1.76 $-1.52 $-1.52
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score 1.429
Altman Z-Prime snapshot only 1.683
Piotroski F-Score 5 5 4 4 5 3 2 2 3 3 1 0 1 1 2 2 2 2 3 3 3
Beneish M-Score -2.11 -0.98
Ohlson O-Score snapshot only -0.542
ROIC (Greenblatt) snapshot only -96.89%
Net-Net WC snapshot only $1.39
EVA snapshot only $-156537080.00
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only BB
Credit Score 45.42 35.90 46.08 36.86 42.88 43.26 44.51 33.39 32.98 33.35 31.83 42.35 31.70 31.86 32.85 32.67 32.53 32.37 32.15 42.28 42.276
Credit Grade snapshot only 12
Credit Trend snapshot only 9.610
Implied Spread (bps) snapshot only 475.000
Industry Credit Rank snapshot only 36
Sector Credit Rank snapshot only 34

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms